Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...

Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations ...

On May 22, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company, received a delisting notice from the Nasdaq Listing Qualifications Department due to non-compliance with specific ...

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional ...

Silexion Therapeutics completes a preclinical study on SIL204 for KRAS-driven cancers, anticipating results in coming days.

GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ:SLXN), a micro-cap biotech firm with a market capitalization of $5.92 million focusing on RNA interference therapies for KRAS-driven cancers ...

Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations ...

SILEXION THERAPEUTICS CORP CONSOLIDATED STATEMENTS OF OPERATIONS (U.S. dollars in thousands, except share data) Year ended December 31 2024 ...

Grand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA ...